Arrigo M,Jessup M,Mullens W,Reza N,Shah AM,Sliwa K .2020 .Acute heart failure. Nat Rev Dis Primers, 6(1) : 16.
Mullens W,Damman K,Harjola VP,Mebazaa A,Brunner-La Rocca HP,Martens P .2019 .The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Euor J Heart Fail, 21(2) : 137-55.
Shah H,Salahudin M,Jan MU,Altaf AJJ .2019 .Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial. J Pak Med Assoc, 69(12) : 1794-9.
Maaten Ter,Valente JM,Damman MA,Hillege K,Navis HL,Voors G,A G .2015 .Diuretic response in acute heart failurepathophysiology, evaluation, and therapy. Am Heart J, 12(3) : 184-92.
Butler J,Usman MS,Khan MS,Greene SJ,Friede T,Vaduganathan M .2020 .Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and metaanalysis. ESC Heart Fail, 7(6) : 3298-309.
Biegus J,Voors AA,Collins SP,Kosiborod MN,Teerlink JR,Angermann CE .2023 .Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J, 44(1) : 41-50.
Matsumura K,Sugiura TJ .2019 .Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. Cardiovasc Ultrasound, 17(1) : 26.
Garg V,Verma S,Connelly K. .2019 .Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis, 62(4) : 349-57.
Groenewegen A,Rutten FH,Mosterd A,Hoes AW .2020 .Epidemiology of heart failure. Eur J Heart Fail, 22(8) : 1342-56.
Ibrahim A,Ghaleb R,Mansour H,Hanafy A,Mahmoud NM,Abdelfatah Elsharef M .2020 .Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients with Decompensated Heart Failure and Reduced Ejection Fraction. Front Cardiovasc Med, 7 : 602251.
McDonagh TA,Metra M,Adamo M,Gardner RS,Baumbach A,Böhm M .2021 .ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Euro Heart J, 42(36) : 3599-726.
Khwaja A. KDIGO .2012 .clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 120(4) : c179-c84.
Felker GM,Ellison DH,Mullens W,Cox ZL,Testani J. .2020 .Diuretic therapy for patients with heart failure: JACC state-ofthe-art review. J Am Coll Cardiol, 75(10) : 1178-95.
Brisco‐Bacik MA,Ter Maaten JM,Houser SR,Vedage NA,Rao V,Ahmad T .2018 .Outcomes associated with a strategy of adjuvant metolazone or high‐dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc, 7(18) : e009149.
Wilcox CS,Shen W,Boulton DW,Leslie BR,Griffen SC .2018 .Interaction Between the Sodium‐Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc, 7(4) : e007046.
Nakagaito M,Joho S,Ushijima R,Nakamura M,Kinugawa KJ .2019 .Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circ Rep, 1(10) : 405-13.
Voors AA,Damman K,Teerlink JR,Angermann CE,Collins SP,Kosiborod M .2022 .Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail, 24(10) : 1844-52.
. .. 2023 Accepted: August 8, 23 : 2023.